Canid – an end-to-end platform for vaccine automation and management – recently announced that it has closed $1.5 million in new funding to expand its geographic footprint to ten new states across the U.S. and bring new tools to manage vaccine patient populations. This funding round was led by SeedtoB Capital, an early-stage fund focused on healthcare innovation and artificial intelligence, with participation from FJ Labs, Alumni Ventures, I2BF, and MKT1.
Canid’s workflow automation solution tackles the complexity of vaccine operations, a vital but historically low-margin service for pediatric and other medical practices. And by ordering and purchasing vaccines, managing billing, and leveraging its network to negotiate stronger rates and maximize reimbursement, Canid mitigates clinical and administrative workload.
Canid’s provider-friendly solution eliminates the need for manual data entry and record-keeping, optimizes inventory in real-time, and empowers practices to run large-scale vaccine clinics. And Canid’s unique suite of tools offers practices a unified way to engage patients and close care gaps, while minimizing provider burnout and delivering higher-quality care.
KEY QUOTES:
“Vaccinations have been taken for granted for decades. They’re the #1 most valuable public health tool we have as a society, and yet they’re always the last priority for our healthcare system. We’re at a point where doctors and patients alike see vaccines as a burden instead of the life-saving preventative care interventions that they are. Our goal at Canid is to change that. By eliminating the burden out of giving and receiving vaccines, we hope to make it exciting again to take part. This starts at the doctor’s office, where a typical pediatrician’s office will give vaccines to hundreds of kids per day.”
— Pedro Sanchez de Lozada, founder and CEO of Canid
“Canid is currently live in 4 states, 3 of which have been added in the past quarter. We’re excited to support Pedro and team to expand across the Southwest and Midwest United States to meet the demand for a new way to vaccinate. As Canid works with larger and larger swaths of the population country-wide, new tools enabling the company to improve vaccination rates will be critical to expanding the impact of their methodology.”
— Ritesh Sharma, Managing Partner at SeedtoB Capital
